Financial reports
10-Q
2023 Q3
Quarterly report
13 Nov 23
10-Q
2023 Q2
Quarterly report
21 Aug 23
NT 10-Q
Notice of late quarterly filing
14 Aug 23
10-Q
2023 Q1
Quarterly report
15 May 23
10-K/A
2021 FY
Annual report (amended)
28 Apr 23
10-K/A
2021 FY
Annual report (amended)
28 Apr 23
10-K
2022 FY
Annual report
14 Apr 23
NT 10-K
Notice of late annual filing
31 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
10 Aug 22
Current reports
8-K
Regulation FD Disclosure
15 Apr 24
8-K
SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results
29 Mar 24
8-K
Entry into a Material Definitive Agreement
8 Mar 24
8-K
SAB Biotherapeutics Announces Executive Leadership Change
2 Feb 24
8-K
Entry into a Material Definitive Agreement
26 Jan 24
8-K
Other Events
25 Jan 24
8-K
Regulation FD Disclosure
19 Jan 24
8-K
SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split
3 Jan 24
8-K
SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying
29 Nov 23
8-K
Amendments to Articles of Incorporation or Bylaws
22 Nov 23
Registration and prospectus
S-8
Registration of securities for employees
23 Feb 24
424B5
Prospectus supplement for primary offering
26 Jan 24
S-3/A
Shelf registration (amended)
20 Nov 23
S-3
Shelf registration
3 Nov 23
D
$7.50 mm in equity / options, sold $7.50 mm, 13 investors
16 Oct 23
S-3
Shelf registration
21 Aug 23
AW
Withdrawal of amendment
31 Jul 23
POS AM
Prospectus update (post-effective amendment)
10 Jul 23
RW
Registration withdrawal request
21 Jun 23
S-3
Shelf registration
9 May 23
Other
EFFECT
Notice of effectiveness
29 Nov 23
CORRESP
Correspondence with SEC
24 Nov 23
UPLOAD
Letter from SEC
7 Nov 23
UPLOAD
Letter from SEC
27 Sep 23
CORRESP
Correspondence with SEC
26 Sep 23
UPLOAD
Letter from SEC
25 Sep 23
EFFECT
Notice of effectiveness
31 Aug 23
CORRESP
Correspondence with SEC
28 Aug 23
UPLOAD
Letter from SEC
28 Aug 23
EFFECT
Notice of effectiveness
18 May 23
Ownership
4
Alexandra Kropotova
23 Feb 24
4
Eddie Joe Sullivan
23 Feb 24
4
Christoph Lawrence Bausch
23 Feb 24
4
Michael King
23 Feb 24
4
Samuel J Reich
23 Feb 24
SC 13G/A
COMMODORE CAPITAL LP
14 Feb 24
SC 13G
RTW INVESTMENTS, LP
14 Feb 24
SC 13G/A
Radcliffe Capital Management, L.P.
14 Feb 24
4
Eddie Joe Sullivan
8 Dec 23
SC 13G
BIOTECHNOLOGY VALUE FUND L P
4 Dec 23